CA3253365A1 - CRYSTALLINE FORMS OF A TYK2 INHIBITOR AND THEIR USES - Google Patents

CRYSTALLINE FORMS OF A TYK2 INHIBITOR AND THEIR USES

Info

Publication number
CA3253365A1
CA3253365A1 CA3253365A CA3253365A CA3253365A1 CA 3253365 A1 CA3253365 A1 CA 3253365A1 CA 3253365 A CA3253365 A CA 3253365A CA 3253365 A CA3253365 A CA 3253365A CA 3253365 A1 CA3253365 A1 CA 3253365A1
Authority
CA
Canada
Prior art keywords
crystalline form
powder
diffraction pattern
ray diffraction
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3253365A
Other languages
English (en)
French (fr)
Inventor
Kolbot By
Travis Remarchuk
Original Assignee
Alumis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alumis Inc filed Critical Alumis Inc
Publication of CA3253365A1 publication Critical patent/CA3253365A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3253365A 2022-05-13 2023-05-12 CRYSTALLINE FORMS OF A TYK2 INHIBITOR AND THEIR USES Pending CA3253365A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263341528P 2022-05-13 2022-05-13
US63/341,528 2022-05-13
US202263405577P 2022-09-12 2022-09-12
US63/405,577 2022-09-12
PCT/US2023/021986 WO2023220338A1 (en) 2022-05-13 2023-05-12 Crystalline forms of a tyk2 inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
CA3253365A1 true CA3253365A1 (en) 2023-11-16

Family

ID=86760338

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3253365A Pending CA3253365A1 (en) 2022-05-13 2023-05-12 CRYSTALLINE FORMS OF A TYK2 INHIBITOR AND THEIR USES

Country Status (11)

Country Link
EP (1) EP4522602A1 (enExample)
JP (1) JP2025516683A (enExample)
KR (1) KR20250009492A (enExample)
CN (1) CN119907791A (enExample)
AU (1) AU2023269081A1 (enExample)
CA (1) CA3253365A1 (enExample)
CL (1) CL2024003456A1 (enExample)
IL (1) IL317011A (enExample)
MX (1) MX2024014000A (enExample)
TW (1) TW202409007A (enExample)
WO (1) WO2023220338A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428571A (zh) * 2022-10-10 2024-07-16 美商雅盧米斯公司 Tyk2抑制劑之晶型及其用途
WO2026019902A1 (en) * 2024-07-16 2026-01-22 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250048T1 (hr) * 2018-10-22 2025-03-28 Alumis Inc. Inhibitori tyk2 i njihova uporaba

Also Published As

Publication number Publication date
KR20250009492A (ko) 2025-01-17
JP2025516683A (ja) 2025-05-30
CL2024003456A1 (es) 2025-04-25
AU2023269081A1 (en) 2024-11-28
CN119907791A (zh) 2025-04-29
TW202409007A (zh) 2024-03-01
WO2023220338A1 (en) 2023-11-16
EP4522602A1 (en) 2025-03-19
MX2024014000A (es) 2025-02-10
IL317011A (en) 2025-01-01

Similar Documents

Publication Publication Date Title
AU2020220512B2 (en) FGFR inhibitor compound in solid form and preparation method therefor
EP3216790B1 (en) Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof
AU2023269081A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
EP1866286B1 (en) Pyridine derivatives useful as inhibitors of pkc-theta
US20250376459A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
WO2016151304A1 (en) Novel polymorphic form x of nilotinib dihydrochloride hydrate
US20260138965A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
US20250263378A1 (en) Solid forms
WO2026019902A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
WO2024081603A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
WO2026019908A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
US20240368185A1 (en) Macrocyclic azolopyridines
WO2026019900A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
TW202610625A (zh) Tyk2抑制劑之晶型及其用途
TW202610624A (zh) Tyk2抑制劑之晶型及其用途
CN110903291B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
CN115772123A (zh) 固体形式
CN117120425A (zh) 鞘氨醇-1-磷酸酯受体激动剂的晶体形式
WO2023125275A1 (zh) 氨基嘧啶类化合物的盐及其用途

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241112

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250131

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250131

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250131

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250217